Bright Minds Biosciences Inc. (DRUG) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
9.79
↑+321% vs avg
5yr avg: 2.33
30Y Low0.9·High5.1
ROE
↑
-27.9%
↓+60% vs avg
5yr avg: -69.2%
30Y Low-186%·High-28%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
DRUG Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Bright Minds Biosciences Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $832M | $417M | $5M | $6M | $15M | $64M | — | — |
| Enterprise Value | $772M | $334M | $-558235 | $-722797 | $4M | $44M | — | — |
| P/E Ratio → | -91.27 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 9.79 | 5.09 | 0.91 | 0.90 | 1.44 | 3.30 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
DRUG EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
DRUG Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -27.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -27.9% | -27.9% | -46.2% | -86.0% | -100.0% | -85.9% | -112.2% | -185.6% |
| ROA | -27.0% | -27.0% | -43.2% | -77.7% | -93.2% | -82.7% | -92.0% | -144.0% |
| ROIC | — | — | — | — | — | — | — | — |
| ROCE | -31.8% | -31.8% | -43.0% | -83.7% | -98.2% | -85.7% | -110.9% | -185.6% |
DRUG Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $83M exceeds total debt of $125777, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.01 | -1.01 | -1.01 | -1.09 | -1.02 | -1.10 | -0.63 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -541.45 | -541.45 | — | — | — | — | — | — |
Net cash position: cash ($83M) exceeds total debt ($125777)
DRUG Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Bright Minds Biosciences Inc.'s current ratio of 36.10x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 24.26x to 36.10x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 36.10 | 36.10 | 11.32 | 24.26 | 8.11 | 31.38 | 5.82 | 2.18 |
| Quick Ratio | 36.10 | 36.10 | 11.32 | 24.26 | 8.11 | 31.38 | 5.82 | 2.18 |
| Cash Ratio | 35.53 | 35.53 | 10.82 | 24.03 | 7.90 | 30.94 | 5.30 | 2.18 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
DRUG Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Bright Minds Biosciences Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $7M | $4M | $4M | $2M | $2M | $1M | $1M |
Peer Comparison
Compare DRUG with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 DRUGYou | $832M | -91.3 | — | — | — | — | -27.9% | — | — |
 CMPS | $952M | -3.2 | — | — | — | — | -565.3% | — | — |
 ATAI | $969M | -4.3 | — | — | 100.0% | -33341.2% | -82.7% | -45.0% | — |
 MNMD | $2B | -10.0 | — | — | — | — | -64.1% | -389.5% | — |
 CYBN | $304M | -13.7 | — | — | — | — | -42.8% | -115.8% | — |
 NRXP | $85M | -2.3 | — | — | — | -1324.4% | — | — | — |
 ACAD | $4B | 9.8 | 26.7 | 36.5 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 AXSM | $11B | -59.1 | — | — | 92.6% | -26.5% | -252.1% | -1906.7% | — |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 PRAX | $10B | -24.5 | — | — | — | — | -45.8% | -65.0% | — |
 LLY | $896B | 41.3 | 29.8 | 99.9 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
| Healthcare Median | — | 22.2 | 14.4 | 18.6 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See DRUG's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DRUG Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DRUG vs CMPS
Side-by-side business, growth, and profitability comparison vs COMPASS Pathways plc.
Start ComparisonDRUG — Frequently Asked Questions
Quick answers to the most common questions about buying DRUG stock.
What is Bright Minds Biosciences Inc.'s P/E ratio?
Bright Minds Biosciences Inc.'s current P/E ratio is -91.3x. This places it at the 50th percentile of its historical range.
What is Bright Minds Biosciences Inc.'s ROE?
Bright Minds Biosciences Inc.'s return on equity (ROE) is -27.9%. The historical average is -92.0%.
Is DRUG stock overvalued?
Based on historical data, Bright Minds Biosciences Inc. is trading at a P/E of -91.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.